Brand Naming: Brand Acumen Details the Evaluation Behind Product Names Still in Use After 25 Years

• According to Brand Acumen, the Xbox® name it created for Microsoft reaches 25 years in the market in 2026.
• Brand Acumen's published portfolio spans consumer and pharmaceutical names, including Escalade®, Powerade®, Galaxy®, Humira® and FreeStyle Libre®.
• Validation methods vary widely across the naming industry, from online surveys to moderated one-on-one interviews.

New York, NY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Technology product names rarely outlast the products they were built for. In 2026, the Xbox® name reached 25 years in market, still carrying Microsoft's console line, a span that outlives most hardware naming in the category. Brand Acumen, the brand naming firm that created it, points to the evaluation done before a name is chosen as what separates names that last from names that only test well at launch.

"Tech names go obsolete. Xbox® has been around for 25 years," said Bill Smith, Founder and CEO of Brand Acumen. "That's a long time for a name in this business."

How the brand naming process works

A naming engagement runs in six phases, each producing a deliverable.

Phase	Role of the naming firm	What the client receives
Naming strategy	Defines what the name has to accomplish strategically, competitively, linguistically, legally and, in regulated categories, before a reviewing authority, prior to name creation	A brief specifying what the name has to accomplish
Creative generation	Develops several hundred coined and descriptive candidates, filtered continuously against the brief	A candidate pool narrowed by elimination
Linguistic screening	Tests candidates for pronunciation, misreading, unintended meaning and cultural associations across target languages	A short list filtered for language risk
Trademark evaluation	Assesses candidates for conflict in the relevant classes and jurisdictions	A short list screened for conflict
Validation	Tests finalists with the intended audience	Evidence for the recommendation
Regulatory filing	In regulated categories, supports or prepares the naming dossier for the reviewing authority	A submission defending the candidate

Evaluation and validation decide which name candidates survive

When trademark evaluation comes after a client has picked favorites, those options are often already taken by the time counsel reviews them. A typical program starts with several hundred candidates, and elimination plays a key role in this phase of the process. Each round removes names for a specific reason, and what reaches the client is a short list that has already survived the brief.

Brand Acumen runs trademark and linguistic risk assessment on every candidate before it is presented, so the list a client reviews has already been examined for conflict and for linguistic risk in the markets where the name will operate. The assessment is not a legal opinion, and counsel still conducts the formal search and files the application.

"We do the trademark and linguistic work first, so the list a client sees is a list they can act on," Smith said.

Validation then applies the same discipline to the finalists. Brand Acumen validates names with people rather than preference scores. This involves prescheduled one-on-one interviews with a live moderator, an approach the firm calls QualiQuantitative, in which the moderator hears how a respondent pronounces the name, where they hesitate, how they interpret it and what associations it creates. The aim is diagnosing how a name performs, not asking people to vote for a favorite. ReLAA, the firm's Relational Linguistics Algorithmic Analysis program, models each candidate's behavior across languages and cultures before any respondent sees it. The firm applied the method on the Escalade® program for Cadillac, a nameplate nearing its third decade, testing candidates with SUV dealers and consumers in the segment.

Pharmaceutical names add a regulator's review

A consumer name has to be pronounceable, distinctive and defensible. A pharmaceutical name has to be all of that and then satisfy a regulator's review of look-alike and sound-alike confusion. In the United States, the sponsor submits a proprietary name request to the FDA. In Europe an invented-name submission goes to the European Medicines Agency (EMA). Each region has its own safety assessment and review process for conflicts with existing drug names and INN stems. Brand Acumen writes those submissions and works across both tracks. The firm's published portfolio in this space includes Humira®, Lantus®, Evenity® and FreeStyle Libre®.

Over three decades and more than 2,000 names, Brand Acumen has seen which names succeed, fail legal review, create linguistic problems, test poorly, age badly or become an enduring commercial asset. That kind of record is built by naming products and following them through the market over decades. A name like Xbox®, still in the market 25 years on, is where that evaluation shows its result. That accumulated judgment is difficult to reproduce from a methodology alone.

Frequently Asked Questions

Question: What does a brand naming firm actually do?

Answer: A brand naming firm takes an engagement from strategy through validation: defining what the name has to accomplish, generating candidates, screening them for linguistic and trademark risk, validating finalists with the intended audience and, in regulated categories, supporting the regulatory filing. Each phase produces a concrete deliverable: a brief, a candidate pool, a screened short list, validation evidence and, where required, a naming dossier.

Question: How are new brand names tested before launch?

Answer: Methods range from online surveys, which record preference at scale, to moderated one-on-one interviews, which record whether a respondent can pronounce the name and how they read it on first encounter. Brand Acumen uses prescheduled moderated interviews, an approach it calls QualiQuantitative, to avoid linguistic issues across 200 languages.

Question: How do new drug names get approved?

Answer: A pharmaceutical brand name is reviewed before launch. The sponsor submits a proprietary name request to the FDA in the U.S. and an invented-name submission to the EMA in Europe. Each regulator assesses the candidate for look-alike and sound-alike confusion, including conflicts with existing drug names and INN stems. Only after that review does the name go to market.

About Brand Acumen

A great name doesn't simply identify a brand. It creates an advantage. For more than 30 years, Brand Acumen has been behind some of the world's most recognized, valuable and enduring names. Xbox®. Escalade®. Powerade®. Galaxy®. PayPal®. Humira®. Lantus®. Evenity®. FreeStyle Libre®. More than 2,000 names across industries, markets and continents. We operate where strategy, creativity, linguistics, research, trademark intelligence and regulatory expertise converge. Because finding a name is easy. Creating one that can break through a crowded category, survive global scrutiny and become a valuable business asset is considerably harder. That is what we do. We don't name for today. We create names with the intelligence, distinction and staying power to lead categories, shape perceptions and build brands for decades to come.

Sarah Evans
Head of PR, Zen Media
sarah@zenmedia.com